Millipore and Novozymes collaborate to supply cell culture supplements

The new products, to be marketed under the brand name CellPrime, will be manufactured by Novozymes and sold through Millipore’s sales organization. The alliance expands the existing relationship between Millipore and Novozymes and will initially focus on developing recombinant human albumin and recombinant human transferrin.

Cell culture supplements help mammalian cells produce the proteins that form the basis of biologic drugs. The CellPrime products are designed to reduce risk and ease regulatory concerns for biopharmaceutical manufacturers. Additionally, these products are expected to help improve the consistency and productivity of customers’ industrial cell culture processes.

Andrew Bulpin, vice president of Millipore’s upstream bioprocessing business unit, said: “Our expanded relationship with Novozymes broadens our commitment to develop a portfolio of high-quality, animal-free alternatives that optimize productivity, address drug safety and ease regulatory approval. Our CellPrime products will give customers a reliable, long-term supply of regulatory compliant supplements and address their desire to eliminate the use of animal-derived products in their manufacturing processes.”